Management of Febrile Neutropenia – a German Prospective Hospital Cost Analysis in Lymphoproliferative Disorders, Non-Small Cell Lung Cancer, and Primary Breast Cancer

Publisher： Karger

E-ISSN： 2296-5262|34|5|241-246

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.34, Iss.5, 2011-04, pp. : 241-246

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain

By Mayordomo José Ignacio   López Andrés   Viñolas Núria   Castellanos Javier   Pernas Sonia   Domingo Alonso Juan   Frau Adolfo   Layola Miquel   Antonio Gasquet José   Sánchez Jordi  

Current Medical Research and Opinion, Vol. 25, Iss. 10, 2009-10 ,pp. : 2533-2542

Informa Healthcare

Access to resources Recommend Favorite

Incidence of Febrile Neutropenia and Myelotoxicity of Chemotherapy: A Meta-Analysis of Biosimilar G-CSF Studies in Breast Cancer, Lung Cancer, and Non-Hodgkin’s Lymphoma

By  

Oncology Research and Treatment, Vol. 32, Iss. 10, 2009-09 ,pp. : 599-604

Karger

Access to resources Recommend Favorite

Successful Management of Crizotinib-Induced Neutropenia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Case Report

By  

Case Reports in Oncology, Vol. 9, Iss. 1, 2016-01 ,pp. : 51-55

Karger

Access to resources Recommend Favorite

Clinical Outcomes and Cost‐effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer

By  

THE BREAST JOURNAL, Vol. 21, Iss. 6, 2015-11 ,pp. : 658-664

John Wiley & Sons Inc

Access to resources Recommend Favorite

Docetaxel in non-small cell lung cancer

By Souquet Pierre-Jean   Geriniere Laurence  

Therapy, Vol. 3, Iss. 5, 2006-09 ,pp. : 579-590

Future Medicine

Access to resources Recommend Favorite